We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Illumina Acquires Advanced Liquid Logic

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Illumina, Inc. announced that it has acquired Advanced Liquid Logic (ALL), a leading provider of liquid handling solutions. ALL, now a wholly owned subsidiary of Illumina, has developed a proprietary “digital microfluidics” technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. This proven technology will enable Illumina to deliver the simplest and most efficient sample-to-answer next-generation sequencing (NGS) workflow.

“For our research customers, ALL’s technology will further streamline the industry's simplest NGS workflow, while for clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business. “ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation.”

One of Illumina's goals is to provide customers with a holistic set of tools to go from biological sample to answer quickly and easily, minimizing the risk of errors and reducing hands-on time in the lab. To that end, Illumina recently announced it is collaborating with leading vendors of liquid handling robotic platforms to make automation solutions for high-throughput sample preparation more accessible. With its acquisition of ALL, Illumina will be able to introduce similar benefits to its low- and mid-throughput customers.

ALL’s versatile technology has been demonstrated across numerous applications, including nucleic acid isolation from various sample types and library generation for next-generation sequencing. Its robust solution has a clear advantage in precisely handling low sample volumes, which is an increasingly important focus for customers.